Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation
NCT ID: NCT01606280
Last Updated: 2014-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
400 participants
OBSERVATIONAL
2011-06-30
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Autologous Stem Cell Transplantation for Patients With AL Amyloidosis
NCT04210791
Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis
NCT00166413
Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis
NCT00344526
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
NCT06192979
Study of Systemic Amyloidosis Presentation and Prognosis
NCT00004374
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. How do lab values at diagnosis such as Creatinine, AST/ALT, total serum protein, serum gamma globulin/immunoglobulin levels affect prognosis in primary amyloidosis?
3. How does degree of organ involvement/number of organs involved affect prognosis in primary amyloidosis?
4. How does initial treatment affect prognosis in primary amyloidosis?
4\. How do the specifics the stem cell transplant protocol affect prognosis in primary amyloidosis?
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* BNP \> 10000
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Morie Gertz
principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11-005003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.